AZN vs BBIO
AZN: AstraZeneca is a global pharmaceutical leader driving innovation in oncology, rare diseases, and specialized biopharmaceuticals to address major unmet medical needs worldwide. BBIO: BridgeBio is a portfolio-based biotech firm focused on translating genetic science into precision therapies for patients with severe genetic disorders.
Side-by-side fundamentals
| Metric | AZN | BBIO | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $161.91 | $84.67 | |
| Market cap as of 2026-08-11 | $184.5B | $16.6B | |
| P/E as of 2026-08-11 | 23.84 | n/a | |
| PEG as of 2026-08-11 | 2.64 | -3.70 | BBIO lower |
| Net margin as of 2026-08-11 | +17.0% | -124.4% | AZN higher |
| Gross margin as of 2026-08-11 | +81.3% | +95.1% | BBIO higher |
| Operating margin as of 2026-08-11 | +22.8% | -90.5% | AZN higher |
| ROE as of 2026-08-11 | +21.7% | -206.7% | AZN higher |
| ROA as of 2026-08-11 | +9.1% | -65.8% | AZN higher |
| Debt / equity as of 2026-08-11 | 0.64 | 8.27 | AZN lower |
| Revenue growth (YoY) as of 2026-08-11 | +8.6% | +355.2% | BBIO higher |
| Revenue CAGR (3y) SEC XBRL | +9.8% | +86.3% | BBIO higher |
| Dividend yield as of 2026-08-11 | +2.0% | n/a | |
| Beta as of 2026-08-11 | 1.36 | 0.95 | |
| 1-year return as of 2026-08-10 close | +10.1% | +81.8% | BBIO higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.